Isolated anti-IDE antibodies are provided. Each of the antibodies comprise an antigen recognition domain comprising the indicated CDR amino acid sequences. Methods of producing same, methods of using same, pharmaceutical compositions comprising same and articles of manufacture are also provided.

The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

Provided herein are methods, compositions, kits, and systems for detecting Epstein Barr virus infection (EBV) in gastric cancer (GC) patients. In particular, provided herein are methods, composition, kits, and systems for diagnosing and treating EBV-positive gastric cancer (EBV.sup.+ GC) in a biological sample of an individual based on the presence and level of antibodies against particular Epstein Barr virus proteins. EBV.sup.+ GC is a distinct subtype of gastric cancer and is associated with unique molecular profiles. Also provided herein are methods for providing more personalized therapy for each of these distinct cancer subtypes and methods for determining an Epstein Barr virus-positive gastric cancer antibody signature, and kits comprising components and protocols for performing the methods of this disclosure.

This document relates to methods and materials involved in identifying and/or treating mammals having a CMV infection. For example, methods and materials for assessing a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) to determine if the mammal is likely to control the CMV infection or to determine if the mammal is unlikely to control the CMV infection are provided. Methods and materials for treating a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) that was either identified as being likely to control the CMV infection or identified as being unlikely to control the CMV infection also are provided.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of a determinant which is set forth in Tables 1 or 2 in a sample derived from the subject, wherein said amount is indicative of the infection type.

Disclosed are a monoclonal antibody that is specific to human cytomegalovirus and binds to human cytomegalovirus with a high affinity, or an antigen-binding fragment thereof, and a method for preparing the antibody. The antibody is also highly effective in neutralizing infections. Also disclosed are an epitope to which the antibody binds, and the use of the antibody in the diagnosis, prevention and treatment of an infected individual.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of a determinant which is set forth in Tables 1 or 2 in a sample derived from the subject, wherein said amount is indicative of the infection type.

The present invention relates to neutralizing monoclonal antibodies or antigen-binding fragments thereof that are specific for and bind with high affinity to Varicella-Zoster Virus, and a preparation method for producing such antibodies. The antibodies of the present invention have high efficiency in neutralizing Varicella-Zoster Virus infection. The present invention also relates to the epitope to which the antibodies bind and the use of the antibodies in the diagnosis, prevention and treatment of infected individuals.

Provided is an antibody or an antigen-binding fragment thereof, a T cell antigen receptor, an immune cell expressing the T cell antigen receptor (TCR), and a preparation method therefor and the use thereof. The TCR can specifically recognize corresponding pMHC complexes, activate TCR T cells, and produce high-level cytokines IFNγ, IL2, TNFα, significantly kill target cells and prolong the life of tumor-bearing mice.

Monoclonal antibodies and antigen binding fragments that specifically bind to the Human Cytomegalovirus (HCMV) pentamer protein complex (gH/gL/UL128/UL130/UL131A) or other gH-containing complexes, and uses thereof.